Clinical Trial

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Study acronym: TYDAL-TIMI 78
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.
Protocol Amendment History 5 changes
critical Enrollment reopened 2026-08-06
notable Enrollment increased: 216 -> 316 participants 2026-08-06
minor Trial arms changed: 3 -> 4 2026-08-06
notable Primary completion pushed: 2026-07 -> 2027-11 2026-08-06
minor Completion pushed: 2026-12 -> 2028-04 2026-08-06
Trial Details
NCT Number NCT07028749
Lead Sponsor Marea Therapeutics
Collaborators: The TIMI Study Group
Conditions Hypertriglyceridemia
Enrollment 316 participants
Start Date 2025-06-30
Primary Completion 2027-11 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-05